SG10201913786SA - Modified rna agents with reduced off-target effect - Google Patents
Modified rna agents with reduced off-target effectInfo
- Publication number
- SG10201913786SA SG10201913786SA SG10201913786SA SG10201913786SA SG10201913786SA SG 10201913786S A SG10201913786S A SG 10201913786SA SG 10201913786S A SG10201913786S A SG 10201913786SA SG 10201913786S A SG10201913786S A SG 10201913786SA SG 10201913786S A SG10201913786S A SG 10201913786SA
- Authority
- SG
- Singapore
- Prior art keywords
- reduced
- modified rna
- target effect
- rna agents
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425907P | 2016-11-23 | 2016-11-23 | |
| US201762548589P | 2017-08-22 | 2017-08-22 | |
| US201762561514P | 2017-09-21 | 2017-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913786SA true SG10201913786SA (en) | 2020-03-30 |
Family
ID=60888585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913786SA SG10201913786SA (en) | 2016-11-23 | 2017-11-22 | Modified rna agents with reduced off-target effect |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11504391B1 (en) |
| EP (1) | EP3544617A4 (en) |
| JP (2) | JP7288852B2 (en) |
| KR (2) | KR20240035907A (en) |
| CN (2) | CN117757791A (en) |
| AU (2) | AU2017363892B2 (en) |
| CA (1) | CA3044598A1 (en) |
| IL (1) | IL266780A (en) |
| MX (1) | MX2019005816A (en) |
| SG (1) | SG10201913786SA (en) |
| WO (1) | WO2018098328A1 (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201792444A1 (en) | 2015-05-06 | 2018-06-29 | Элнилэм Фармасьютикалз, Инк. | COMPOSITIONS ON THE BASIS OF IRNA FOR FACTOR XII (HAGEMAN FACTOR) (F12), PLASMA KALLIKREIN B (FLETCH FACTOR) 1 (KLKB1) AND KININOGEN 1 (KNG1) AND FOSTER OF THE FLETCHER) (1) |
| WO2018098328A1 (en) | 2016-11-23 | 2018-05-31 | Alnylam Pharmaceuticals, Inc. | Modified rna agents with reduced off-target effect |
| FR3060947A1 (en) * | 2016-12-28 | 2018-06-29 | Ynsect | METHOD OF TREATING INSECTS COMPRISING THE SEPARATION OF CUTICLES FROM THE MOLLE PART OF INSECTS THEN SEPARATING THE MOLLE PART INTO THREE FRACTIONS |
| EP3649243A1 (en) * | 2017-07-07 | 2020-05-13 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing contact-activation pathway-associated diseases using irna compositions targeting factor xii (hageman factor) (f12) |
| EP3790557A4 (en) * | 2018-05-07 | 2022-03-02 | Alnylam Pharmaceuticals Inc. | Compositions and methods for improving strand biased |
| WO2019222479A1 (en) * | 2018-05-16 | 2019-11-21 | Alnylam Pharmaceuticals, Inc. | Modified rna agents with reduced off-target effect |
| EP3802824A1 (en) | 2018-06-05 | 2021-04-14 | F. Hoffmann-La Roche AG | Oligonucleotides for modulating atxn2 expression |
| BR112021000538A2 (en) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | OLIGONUCLEOTIDS TO MODULATE RTEL1 EXPRESSION |
| EA202190528A1 (en) * | 2018-08-13 | 2021-04-23 | Элнилэм Фармасьютикалз, Инк. | COMPOSITIONS OF HEPATITIS B VIRUS (HBV) dsRNA AGENTS AND METHODS OF THEIR APPLICATION |
| EA202192733A1 (en) | 2019-04-03 | 2022-03-14 | Бристол-Маерс Сквибб Компани | ANGPTL2 ANTISENSE OLIGONUCLEOTIDES AND THEIR APPLICATIONS |
| CN114402074A (en) * | 2019-07-16 | 2022-04-26 | 国立大学法人东京大学 | RNA molecule, chimeric NA molecule, double-stranded RNA molecule, and double-stranded chimeric NA molecule |
| KR20220062517A (en) | 2019-08-15 | 2022-05-17 | 아이오니스 파마수티컬즈, 인코포레이티드 | Linkage-modified oligomeric compounds and uses thereof |
| MX2022002689A (en) * | 2019-09-03 | 2022-04-07 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of the lect2 gene. |
| EP4058577A1 (en) * | 2019-11-13 | 2022-09-21 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating an angiotensinogen- (agt-) associated disorder |
| WO2021122735A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sept9 inhibitors for treating hepatitis b virus infection |
| EP4077669A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of sbds inhibitors for treating hepatitis b virus infection |
| EP4077671A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of saraf inhibitors for treating hepatitis b virus infection |
| EP4077668A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of scamp3 inhibitors for treating hepatitis b virus infection |
| EP4077670A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of cops3 inhibitors for treating hepatitis b virus infection |
| WO2021130270A1 (en) | 2019-12-24 | 2021-07-01 | F. Hoffmann-La Roche Ag | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| CA3163490A1 (en) | 2019-12-24 | 2021-07-01 | F. Hoffman-La Roche Ag | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| WO2021231211A1 (en) | 2020-05-11 | 2021-11-18 | Genentech, Inc. | Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same |
| JP2023525770A (en) | 2020-05-11 | 2023-06-19 | ジェネンテック， インコーポレイテッド | COMPLEMENT C4 INHIBITORS AND RELATED COMPOSITIONS FOR TREATMENT OF NEUROLOGICAL DISEASES, AND SYSTEMS AND METHODS USING THE SAME |
| JP2023527693A (en) | 2020-05-11 | 2023-06-30 | ジェネンテック， インコーポレイテッド | Complement Component C1R Inhibitors and Related Compositions, Systems, and Methods of Using The Same for Treating Neurological Disorders |
| WO2022038211A2 (en) | 2020-08-21 | 2022-02-24 | F. Hoffmann-La Roche Ag | Use of a1cf inhibitors for treating hepatitis b virus infection |
| EP4214319A2 (en) * | 2020-09-17 | 2023-07-26 | Q-State Biosciences, Inc. | Therapeutic compositions for treating pain via multiple targets |
| EP4279591A1 (en) * | 2021-01-15 | 2023-11-22 | The University of Tokyo | Rna molecule, chimeric na molecule, double-stranded rna molecule, and double-stranded chimeric na molecule |
| EP4291654A2 (en) | 2021-02-12 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| AU2022345098A1 (en) | 2021-09-16 | 2024-04-04 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| WO2023083906A2 (en) | 2021-11-11 | 2023-05-19 | F. Hoffmann-La Roche Ag | Pharmaceutical combinations for treatment of hbv |
| WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
| CN116003494A (en) * | 2022-01-05 | 2023-04-25 | 大睿生物医药科技(上海)有限公司 | Double stranded RNA with nucleotide analogs |
| WO2024098061A2 (en) | 2022-11-04 | 2024-05-10 | Genkardia Inc. | Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2494940T3 (en) | 2004-04-22 | 2014-09-16 | Regado Biosciences, Inc. | Enhanced coagulation factor modulators |
| EP1681347A1 (en) * | 2005-01-18 | 2006-07-19 | Metanomics GmbH & Co. KGaA | Improved methods for double-stranded RNA mediated gene silencing |
| AU2007229161B2 (en) * | 2006-03-23 | 2012-07-12 | Roche Innovation Center Copenhagen A/S | Small internally segmented interfering RNA |
| US20140170191A1 (en) | 2008-10-23 | 2014-06-19 | Hemispher Biopharma, Inc. | Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
| CN102497870A (en) | 2009-06-03 | 2012-06-13 | 戴瑟纳制药公司 | Peptide DICER substrate agents and methods for their specific inhibition of gene expression |
| WO2011109427A2 (en) * | 2010-03-01 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Improving the biological activity of sirna through modulation of its thermodynamic profile |
| US10913767B2 (en) * | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
| EP2646550B1 (en) * | 2010-12-02 | 2015-02-18 | Keygene N.V. | Targeted alteration of dna with oligonucleotides |
| EP2734525A4 (en) * | 2011-07-19 | 2015-03-04 | Univ Idaho | Embodiments of a probe and method for targeting nucleic acids |
| BR122020024443B1 (en) * | 2014-05-01 | 2022-02-22 | Ionis Pharmaceuticals, Inc | Compound and pharmaceutical composition for modulating angptl3 expression |
| KR102630289B1 (en) | 2014-08-20 | 2024-01-31 | 알닐람 파마슈티칼스 인코포레이티드 | Modified double-stranded rna agents |
| US20170369872A1 (en) | 2014-12-18 | 2017-12-28 | Alnylam Pharmaceuticals, Inc. | Reversir tm compounds |
| WO2018098328A1 (en) | 2016-11-23 | 2018-05-31 | Alnylam Pharmaceuticals, Inc. | Modified rna agents with reduced off-target effect |
| EP4041248A4 (en) | 2019-10-11 | 2024-03-20 | Alnylam Pharmaceuticals Inc | Modified oligonucleotides |
-
2017
- 2017-11-22 WO PCT/US2017/063078 patent/WO2018098328A1/en unknown
- 2017-11-22 CA CA3044598A patent/CA3044598A1/en active Pending
- 2017-11-22 SG SG10201913786SA patent/SG10201913786SA/en unknown
- 2017-11-22 KR KR1020247007251A patent/KR20240035907A/en not_active Application Discontinuation
- 2017-11-22 KR KR1020197018071A patent/KR102645243B1/en active IP Right Grant
- 2017-11-22 CN CN202311754990.3A patent/CN117757791A/en active Pending
- 2017-11-22 US US16/461,523 patent/US11504391B1/en active Active
- 2017-11-22 MX MX2019005816A patent/MX2019005816A/en unknown
- 2017-11-22 JP JP2019527517A patent/JP7288852B2/en active Active
- 2017-11-22 AU AU2017363892A patent/AU2017363892B2/en active Active
- 2017-11-22 EP EP17873158.4A patent/EP3544617A4/en active Pending
- 2017-11-22 CN CN201780084435.0A patent/CN110582283B/en active Active
-
2019
- 2019-05-21 IL IL266780A patent/IL266780A/en unknown
-
2022
- 2022-09-30 US US17/937,256 patent/US20230256001A1/en active Pending
-
2023
- 2023-01-20 JP JP2023007453A patent/JP2023053963A/en active Pending
- 2023-09-05 AU AU2023226646A patent/AU2023226646A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11504391B1 (en) | 2022-11-22 |
| JP2023053963A (en) | 2023-04-13 |
| US20230256001A1 (en) | 2023-08-17 |
| JP7288852B2 (en) | 2023-06-08 |
| AU2023226646A1 (en) | 2023-11-16 |
| CN117757791A (en) | 2024-03-26 |
| CA3044598A1 (en) | 2018-05-31 |
| CN110582283A (en) | 2019-12-17 |
| WO2018098328A1 (en) | 2018-05-31 |
| KR20190086001A (en) | 2019-07-19 |
| MX2019005816A (en) | 2019-10-07 |
| EP3544617A4 (en) | 2020-08-05 |
| CN110582283B (en) | 2024-01-02 |
| AU2017363892A1 (en) | 2019-06-13 |
| KR102645243B1 (en) | 2024-03-11 |
| IL266780A (en) | 2019-08-29 |
| AU2017363892B2 (en) | 2023-06-15 |
| KR20240035907A (en) | 2024-03-18 |
| EP3544617A1 (en) | 2019-10-02 |
| JP2019535288A (en) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266780A (en) | Modified rna agents with reduced off-target effect | |
| IL280941A (en) | Modified double-stranded rna agents | |
| ZA201905396B (en) | Trans-replicating rna | |
| HK1243741A1 (en) | Tnfrsf-binding agents and uses thereof | |
| IL255577B (en) | Tigit-binding agents and uses thereof | |
| IL252386B (en) | Targeted rna editing | |
| GB201716957D0 (en) | Absorbent articles with improved cores | |
| IL273595A (en) | Modified cpf1 guide rna | |
| DK3307370T3 (en) | URINARY CATHETRES WITH LIMITED RECYCLABILITY | |
| ZA202001649B (en) | Rna molecules | |
| EP3802827A4 (en) | Modified rna agents with reduced off-target effect | |
| EP3212792A4 (en) | Nucleic acid modifying agents and uses thereof | |
| IL257500A (en) | Modified cullin1 gene | |
| GB201805539D0 (en) | Beneficiating weighting agents | |
| HUE052800T2 (en) | Contrast agents | |
| GB201605354D0 (en) | Modified enzyme | |
| GB201605378D0 (en) | Modified microorganisms | |
| GB201605341D0 (en) | Modified microorganisms | |
| GB201506427D0 (en) | Raven Genetic Enhancement | |
| GB201511459D0 (en) | Sirna microbubble | |
| GB201512216D0 (en) | Agents uses and methods | |
| GB201506892D0 (en) | Genetic enhancement ideas two | |
| GB201505840D0 (en) | Genetic enhancement ideas |